Grass City 20% OFF

HENDERSON, NV / ACCESSWIRE / September 10, 2018 / A fascinating biotech firm DCTH (Delcath Systems, Inc.), has an intriguing treatment for liver cancer. The company has initiated a global Phase 3 clinical trial for patients with intrahepatic cholangiocarcinoma (ICC), using its drug product Melphalan/HDS. DCTH reported that the FDA has approved the design of this phase 3 clinical trial using their Melphalan/HDS drug product under what is called a Special Protocol Assessment. If this is the first time you are hearing about DCTH, start doing your own due diligence right away. DCTH is a very interesting biotechnology company, that seems to be very undervalued in our opinion, and totally under the radar currently. DCTH has a market cap of only a couple million dollars, for a company with a drug closing in on a phase 3 clinical trial this seems quite low. DCTH could start receiving increased attention from the street at anytime. Discovering DCTH before the public at large, and before the company’s phase 3 clinical trial could witness a massive uptrend.

While it’s still relatively unknown, now may be the time to jump on this growth play.

A few CBD and Biotech stocks to consider include: Delcath Systems, Inc. (DCTH), Cara Therapeutics, Inc. (CARA), Insys Therapeutics, Inc. (INSY), Aphria, Inc. (APHQF), and Aurora Cannabis (OTCQX:ACBFF).

Delcath Systems, Inc. (DCTH)

Market Cap: $1.79M Share Price: $1.92

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, just announced that the result of a multicenter analysis of outcomes in patients with intrahepatic cholangiocarcinoma (ICC) treated with CHEMOSAT has been accepted for publication in the journal European Radiology.

Delcath’s investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. DCTH has commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and has initiated a Registration trial called The ALIGN Trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. However, in Europe, their system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.

DCTH investors could be in for a huge windfall if they are able to obtain US approval.

Cara Therapeutics, Inc. (CARA)

Market Cap: $781.48 Share Price: $19.89

Cara Therapeutics, Inc. (CARA), a U.S. biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, announced that it has licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize KORSUVA (CR845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients to Vifor Fresenius Medical Care Renal Pharma Ltd (VFMCRP), a joint company of Vifor Pharma Group (VIFN.VX) and Fresenius Medical Care (FMS) that specializes in treatments for CKD. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to KORSUVA injection for this indication, for which there are currently no approved therapies in the U.S. or E.U. The stock made a huge jump on second quarter financials.

Insys Therapeutics, Inc. (INSY)

Market Cap: $608.80M Share Price: $8.20

Shares of INSYS Therapeutics (INSY) jumped a whopping 40.3% in August, according to data from S&P Global Market Intelligence. The biotech’s massive valuation change came from news about a settlement with the U.S. Department of Justice (DOJ), which seems completely reasonable, followed by a not-so-reasonable increase as shorts covered their positions at the end of the month.

Aphria, Inc. (APHQF)

Market Cap: $3.44B, Share Price: $14.70

Aphria Inc. recently announced that it has signed a Manufacturer’s Representative agreement with We Grow BC Ltd., a Vancouver -based licensed producer of premium cannabis, to become We Grow’s exclusive sales representative across Canada. Investors have jumped on this news, making it one of the hottest marijuana plays in the sector. Today, Aphria announced it has cleared its balance sheet of U.S. cannabis investments and will reenter U.S. market when U.S. federal laws permit, easing the concerns of some investors.

Aurora Cannabis, Inc. (OTCQX:ACBFF)

Market Cap: $5.88B Share Price: $6.17

Another CBD company receiving investor interest from recent new is Aurora Cannabis Inc. (ACBFF). The company recently received a Letter of Intent to establish one of the first medical cannabis production facilities in Malta. The Company received a Letter of Intent from Malta Enterprise for the establishment of a seed-to-pharma cannabis operation, including the construction of a hybrid production facility that will be focused predominantly on the production of oils and derivatives. Operations will be carried out by a new company, to be formed by Aurora and its local partner Cherubino Ltd., the largest pharmaceutical wholesaler in Malta with an operating history of over 100 years. Aurora will be the majority shareholder in the new venture.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and three thousand dollars total by Regal Consulting. LLC, for news commentary articles for DCTH. DCTH and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager


Phone: 1-702-720-6310

Country: United States


SOURCE: ACR Communication, LLC

Stock Symbols